✦ LIBER ✦

Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma

✍ Scribed by Stefano Luminari; Luigi Marcheselli; Stefano Sacchi; Samantha Pozzi; Alessia Bari; Fiorella Ilariucci; Caterina Stelitano; Francesco Angrilli; Antonio Lazzaro; Luca Baldini

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 153 KB
Volume: 115
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.24222

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rituximab in combination with fludarabin

Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma

✍ Stefano Sacchi; Samantha Pozzi; Raffaella Marcheselli; Massimo Federico; Alessan 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB 👁 2 views

## Abstract ## BACKGROUND. The current study was conducted to asses the safety profile and clinical activity of rituximab in combination with fludarabine and cyclophosphamide in patients with recurrent follicular lymphoma (FL). ## METHODS. This study was a noncomparative, multicenter, phase II s

Fludarabine, cyclophosphamide, and ritux

Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-hodgkin lymphoma

✍ Constantine S. Tam; Max Wolf; H. Miles Prince; E. Henry Januszewicz; David Weste 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 138 KB 👁 1 views

Combination therapy with rituximab and i

Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type

✍ Antonio Salar; Eva Domingo-Domenech; Cristina Estany; Miguel A. Canales; Fernand 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 3 views

Combination therapy with fludarabine and

Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma : A phase 2 trial of the Minnie Pearl Cancer Research Network

✍ John D. Hainsworth; Elizabeth R. Vazquez; David R. Spigel; Eric Raefsky; James D 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 2 views

## Abstract ## BACKGROUND The purpose of the current study was to evaluate the efficacy and toxicity of the combination of fludarabine and rituximab, followed by alemtuzumab, as first‐line treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ## METHO

Phase I trial of paclitaxel, carboplatin

Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer

✍ John D. Hainsworth; Howard A. Burris III; Lisa H. Morrissey; F. Anthony Greco 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 3 views

## Background: Topotecan is a new antineoplastic agent with a broad spectrum of activity. the purpose of this phase i trial was to define the maximum tolerated dose of topotecan when added to the widely used combination of paclitaxel and carboplatin. ## Methods: Patients with advanced cancer that

Long-term results of the treatment of pa

Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group

✍ David J. Inwards; Paul A. S. Fishkin; David W. Hillman; David W. Brown; Stephen 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 1 views

## Abstract ## BACKGROUND. The objective of this study was to test cladribine (2‐CDA) alone and in combination with rituximab in patients with mantle cell lymphoma (MCL). ## METHODS. Patients with MCL were treated on 2 sequential trials. In Trial 95‐80‐53, patients received 2‐CDA as initial ther